HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biden DXM Bill Includes Age Limit, Bulk Ingredient Scheduling

This article was originally published in The Tan Sheet

Executive Summary

The Consumer Healthcare Products Association backs Sen. Joe Biden's proposal to set a nationwide age limit on purchases of dextromethorphan-containing OTC drugs, but the group differs with the bill's approach to regulating bulk sales of raw DXM

You may also be interested in...

“Snurf” Abuse Reports Revive Interest In DXM Bills

A recent report of young people suspected of abusing "Snurf" has reignited interest on Capitol Hill in restricting bulk purchases of raw dextromethorphan and an age restriction on OTCs containing the cough suppressant

Dextromethorphan Under Scrutiny For Possible International Regulation

The World Health Organization will consider recommending dextromethorphan and nine other drugs for potential international restrictions, and will base its decisions in part on information provided by FDA

Lingering Side Effects Of Cough/Cold Issues Drive CHPA 2008 Agenda

In the coming year, the Consumer Healthcare Products Association will work to emphasize to Congress the safety and efficacy of OTC drugs approved under FDA's monograph system

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts